Physician profile
Anwar E Monroy
NPI 1568650992
$18,903.93
in general payments reported to CMS, 2019-2025
48 companies · $2,877 in 2025
The $2,877 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,134 · 2020: $2,815 · 2021: $3,021 · 2022: $2,047 · 2023: $2,295 · 2024: $2,715 · 2025: $2,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,850 · Education: $37.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,849.69 |
| Education | $37.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,699.76 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,671.72 | 2019-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $1,210.84 | 2021-2025 | |
| Pfizer INC. | $1,124.98 | 2019-2025 | |
| Lilly USA, LLC | $1,088.41 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $975.41 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $921.86 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $831.44 | 2019-2024 | Xarelto, Spravato |
| Abbvie INC. | $830.13 | 2021-2025 | |
| Novo Nordisk INC | $827.31 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $782.43 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $761.71 | 2019-2025 | Xifaxan |
| Abbott Laboratories | $722.64 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $706.52 | 2019-2025 | Jardiance |
| Allergan, INC. | $574.89 | 2019-2020 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anwar Monroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.